A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis
Latest Information Update: 01 Dec 2021
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOMS
- Sponsors Novartis
- 01 Nov 2021 Results of PSM-based ITC analysis from following clinical trials: EXPAND, INFORMS, FREEDOMS, FREEDOMS-II, TRANSFORMS, ASCLPEIOS-I and ASCLPEIOS-II published in the Current Medical Research and Opinion
- 15 Oct 2021 Results assessing effect of ofatumumab on the percentage whole brain volume change (PBVC) over 2 years compared with historical placebo in patients with RMS from ASCLEPIOS , FREEDOMS AND FREEDOM-II STUDYpresented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Sep 2019 Acording to a Novartis Media Release, data from this trial was presented at the presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), in Stockholm, Sweden.